Business Suspension and Production Site Reorganization at a Chinese Subsidiary
First written in FY2023. 2 of 6 entries say "Restated". Latest entry: 2026-05-14.
No other company in this theme has enough history to compare yet.
- 2026-05-14RestatedEarnings
「東莞立丸奈米科技有限公司, formerly a consolidated subsidiary, was excluded from the scope of consolidation in the current fiscal year because its liquidation was completed on 17 July 2025.」
The completion of the liquidation of the Chinese subsidiary and its exclusion from the scope of consolidation have been reconfirmed. - FY2026-H1AchievedAnnual report
「As 東莞立丸奈米科技有限公司, formerly a consolidated subsidiary, completed its liquidation on 17 July 2025, it has been excluded from the scope of consolidation from the interim consolidated accounting period under review.」
Regarding the Chinese subsidiary, the process has moved from the previous stage of suspending operations, dissolution and liquidation to the stage where liquidation was completed as of 17 July 2025 and the subsidiary was excluded from the scope of consolidation. - FY2025RestatedAnnual report
「At a meeting of the Board of Directors held on 13 November 2023, 東莞立丸奈米科技有限公司 resolved to dissolve and is currently undergoing liquidation procedures.」
The Chinese subsidiary is undergoing dissolution and liquidation procedures following the suspension of its business; completion of the liquidation has not been disclosed. - FY2024Recognition of business exit lossAnnual report
「Business exit loss 35,493」
The company recognized a business exit loss of ¥35.493 million, apparently related to the suspension, dissolution and liquidation of the Chinese subsidiary's business, as an extraordinary loss. However, the filing does not state that the dissolution and liquidation procedures have been completed. - FY2024-Q2AdvancedAnnual report
「At a meeting of the Board of Directors held on 13 November 2023, the company resolved to dissolve and liquidate its consolidated subsidiary, 東莞立丸奈米科技有限公司.」
Regarding the Chinese subsidiary, the company proceeded from a policy of suspending the business to a resolution by the Board of Directors to dissolve and liquidate it. Liquidation is scheduled to be completed after procedures under local laws are finished, and the dissolution and liquidation themselves have not yet been completed. - FY2023First statedAnnual report
「At a meeting of the Board of Directors held on 15 May 2023, the company resolved to suspend the calcium carbonate manufacturing and sales business of its consolidated subsidiary, 東莞立丸奈米科技有限公司. Since the subsidiary was established, it has leased land from 立台有限公司 for use as a factory site. 東莞市道滘鎮資産経営管理有限公司, the management company of the industrial park where the site is located, requested that 立台有限公司 vacate the site. As 立台有限公司 intends to comply with the request, the company also decided to suspend the business and comply with the request to vacate the site. The business is scheduled to be suspended by the end of 2023.」
Regarding the consolidated subsidiary in China, the company resolved to suspend its calcium carbonate manufacturing and sales business by the end of 2023 in response to a request to vacate the site from the industrial park management company. The subsidiary's ownership ratio is 51% and its stated capital is US$3,000 thousand; the impact on profit or loss is still under review.